User Notice: The old Support number is no longer in use. To reach Support please call +44 (0) 203 8794 460

Share Name Share Symbol Market Type Share ISIN Share Description
Iq-ai Limited LSE:IQAI London Ordinary Share JE00BD4H0R42 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  -0.75 -11.63% 5.70 6,768,205 15:55:07
Bid Price Offer Price High Price Low Price Open Price
5.50 5.90 6.45 5.65 6.45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Retailers 0.16 -0.76 -0.82 7.0
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:59 O 32,700 5.84 GBX

Iq-ai (IQAI) Latest News

More Iq-ai News
Iq-ai Takeover Rumours

Iq-ai (IQAI) Share Charts

1 Year Iq-ai Chart

1 Year Iq-ai Chart

1 Month Iq-ai Chart

1 Month Iq-ai Chart

Intraday Iq-ai Chart

Intraday Iq-ai Chart

Iq-ai (IQAI) Discussions and Chat

Iq-ai Forums and Chat

Date Time Title Posts
15/7/201921:37Imaging Quantification - Artificial Intelligence1,739

Add a New Thread

Iq-ai (IQAI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-07-15 15:30:015.8432,7001,909.68O
2019-07-15 15:28:586.10100,0006,100.00O
2019-07-15 15:24:225.636,204348.98O
2019-07-15 15:23:215.6210,000562.00O
2019-07-15 15:04:345.8025,0001,450.00O
View all Iq-ai trades in real-time

Iq-ai (IQAI) Top Chat Posts

DateSubject
15/7/2019
09:20
Iq-ai Daily Update: Iq-ai Limited is listed in the General Retailers sector of the London Stock Exchange with ticker IQAI. The last closing price for Iq-ai was 6.45p.
Iq-ai Limited has a 4 week average price of 2.35p and a 12 week average price of 1.03p.
The 1 year high share price is 6.85p while the 1 year low share price is currently 0.98p.
There are currently 127,489,352 shares in issue and the average daily traded volume is 3,958,920 shares. The market capitalisation of Iq-ai Limited is £7,266,893.06.
14/7/2019
14:05
hedgehog 100: Having been vindicated on the IQAI share price, now is an apposite time to consider what David Smith said last year re. future IQAI sales. Well, in one of his investor presentations last August, he revealed that his plan is to deliver revenues of $20M. to $30M. annual within the next few years on existing products but double that with ‘planned’ products. And in view of his extraordinary track record with Biocompatibales, Carl Zeiss, and Tenaxis Medical, this plan has to be taken seriously: https://uk.advfn.com/stock-market/london/flying-brand-FBDU/share-news/Flying-Brands-Limited-Appointment-of-CEO-to-the-Op/78009277 How would such stellar growth be achieved? Well, David Smith's interviews on Proactive Investors, combined with IQAI's RNSes, give an indication of what could well be in store here: • Fielding of own sales team. • Reseller distribution agreements. • A joint venture from a large company, involving a large cash injection. • Move into liver from kidney and brain. • Continued development of the gadolinium-free contrast agent (for imaging) product. • Continued movement into deep learning and artificial intelligence, and use of the click fee. And with a relatively low cost base, which won't go up as proportionally as sales, the company should surge into great profitability on the back of this sales growth.
04/7/2019
14:20
tidy 2: Hedgehog100Posts: 575Price: 4.25Strong BuyRE: NiceToday 14:16The fact that FDA approval for Stonechecker software has taken so long shows how rigorous the process is, how advanced the product is, and also what a great achievement approval will be.And one that will be monumental for IQAI's development, because America is such a vast and well-funded healthcare market, which is at the forefront of applying new technology.This won't therefore be your 'average' good news: it will be gold-plated, company-transformative, 'talk of the town' news.Therefore, I think that we can expect a very big immediate rerating upwards in the share price ... but that should be just for starters.The general upward momentum could continue for weeks, months, and years.And in terms of business, IQAI is chaffing at the bit to start selling StoneChecker into the multi trillion dollar US healthcare market, and has been investing into its business ahead of that, a very positive sign.IQAI also appears to have a range of potential US reseller agreements lined up, which could be ready for signing once FDA marketing approval is received, if not earlier.In effect, the FDA approval will be like removing a 'plug' to unleash a stream of positive IQAI newsflow.So I would certainly anticipate that the IQAI share price will hit multiples of its current level in the not too distant future.
22/6/2019
13:40
hedgehog 100: Let's "seek truth from facts" and examine Trevor Brown's record: the share price performance during his two previous listed directorships prior to here. - 1. ADVANCED ONCOTHERAPY (AVO) (formerly CareCapital): 28.6.12 - 30.8.13. Share price rise from approx. 25p to approx. 92p: GAIN OF C. 268%. 28/06/2012 07:01 UK Regulatory (RNS & others) CareCapital Group plc Appointment of Director "CareCapital (AIM: CARE) is pleased to announce the appointment of Trevor Brown as a Non-executive Director with immediate effect. Trevor Brown (66) has been a strategic investor in real estate and equities for more than 30 years. Mr Brown is a director of Free Association Books Limited in London. He has a beneficial interest as at the date of this announcement in 15,334,001 ordinary shares of CareCapital, representing 9.38% of the Company's current issued share capital. There is no further information required to be disclosed in relation to Rule 17 and Schedule 2 (g) of the AIM Rules for Companies. Commenting on the appointment, Dr Mike Sinclair, CareCapital's CEO, said, "I am pleased that Trevor has agreed to join the Board as a Non-executive Director. He is, and has been, a supporter of our plans to refocus CareCapital on the provision of advanced cancer treatment services. His experience and track record will greatly benefit our Board, our management team and our shareholders. I welcome him to CareCapital." ..." https://uk.advfn.com/stock-market/london/advanced-oncotherapy-AVO/share-news/CareCapital-Group-plc-Appointment-of-Director/52918775 30/08/2013 07:15 UK Regulatory (RNS & others) Advanced Oncotherapy PLC Directorate Change " ...Advanced Oncotherapy announces that Non-Executive Director Trevor Brown has resigned from the Board for health reasons. Trevor became a director in June 2012 and has been, and remains, a significant investor in the Company and major supporter of its new cancer services strategy. Advanced Oncotherapy's CEO, Dr Mike Sinclair, said, "Trevor was an early supporter of our change of strategy to become a cancer treatment services business. We benefited both from his advice during a time of transition and his investment in the Company. On behalf of the Board and all of our shareholders, I thank him for his involvement. We wish him a speedy return to good health." Trevor Brown added, "I have enjoyed being a director of Advanced Oncotherapy and participating in the design and formulation of a strategy that I believe will yield substantial returns for shareholders. I remain a committed supporter of, and shareholder in, the Company and look forward to its continuing development and growth." ..." https://uk.advfn.com/stock-market/london/advanced-oncotherapy-AVO/share-news/Advanced-Oncotherapy-PLC-Directorate-Change/59008450 2. FEEDBACK (FDBK): 13.1.14 - 8.6.17 Share price rise from approx. 0.85p to approx. 3.75p: GAIN OF C. 341%. 13/01/2014 08:00 UK Regulatory (RNS & others) Feedback PLC Directorate Change "The Company announces that Trevor Brown and Tom Charlton have joined the board with immediate effect as Non-Executive Directors. Mr Brown, aged 67, has been a strategic investor in real estate and equities for more than 30 years. He was most recently a director of Advanced Oncotherapy plc where he was involved in the strategy of transition to the provision of advanced cancer treatment services. …" https://uk.advfn.com/stock-market/london/feedback-FDBK/share-news/Feedback-PLC-Directorate-Change/60635638 08/06/2017 13:11 UK Regulatory (RNS & others) Feedback PLC Directorate Change "Feedback plc (AIM: FDBK), the medical imaging software company, announces that Trevor Brown, has resigned as a Non-Executive Director of Feedback, with immediate effect ... Dr Alastair Riddell, Non-Executive Chairman, commented: "I should like to thank Trevor for his invaluable support of the Company following its readmission in 2014 which has enabled it to achieve substantial progress to date. ..." https://uk.advfn.com/stock-market/london/feedback-FDBK/share-news/Feedback-PLC-Directorate-Change/74957678 = AVERAGE INCREASE OF c. 304.5%. In summary, on the key metric of share price performance, Trevor Brown has really delivered the goods: an on average QUADRUPLING of these two share prices. Compare this to all the miserably under performing directors of penny shares, and Trevor Brown's achievements look even better. Trevor Brown is one of the very few consistent successes in this arena.
19/6/2019
15:49
hedgehog 100: The 'gang of four' top management at IQAI is a veritable dream team of talent and ability: Trevor Brown, CEO of IQAI HTTP://www.flyingbrands.co.uk/ David Smith, Chief Operating Officer and CEO of the group's two operating businesses, StoneChecker Software and Imaging Biometrics Nick Stevens, CEO of Stone Checker Software Ltd HTTP://www.imagingbiometrics.com/what-we-offer/product-services/ib-stonechecker/ Michael Schmainda, CEO of Imaging Biometrics HTTP://www.imagingbiometrics.com/ And all four have invested significant sums into Flying Brands / IQAI within the last few/several months ... mostly at a price of 2p per share or more: 11/09/2018 07:01 UK Regulatory (RNS & others) Flying Brands Limited Director/PDMR Shareholding "Flying Brands, the parent company of StoneChecker(R) and Imaging Biometrics(R) focused on advanced and state of the art medical software and services, was notified on 10 September 2018 that David Smith, CEO to the Operating Subsidiaries of the Company, acquired 1,000,000 ordinary shares in the Company on 10 September 2018, representing 0.83% of the Company's issued share capital, at a price of 2.48 pence per share." http://uk.advfn.com/stock-market/london/flying-brand-FBDU/share-news/Flying-Brands-Limited-Director-PDMR-Shareholding/78229870 11/09/2018 09:00 UK Regulatory (RNS & others) Flying Brands Limited Director/PDMR Shareholding "Flying Brands, the parent company of StoneChecker(R) and Imaging Biometrics(R) focused on advanced and state of the art medical software and services, was notified on 10 September 2018 that Nick Stevens, CEO to Stone Checker Software Ltd, acquired 1,200,000 ordinary shares in the Company on 10 September 2018, representing 1% of the Company's issued share capital, at a price of 2.5 pence per share. Previously to this notification, Mr Stevens held 2,000,000 ordinary shares in the Company. Therefore Nick Steven's total shareholding represents 2.66% of the Company's issued share capital." http://uk.advfn.com/stock-market/london/flying-brand-FBDU/share-news/Flying-Brands-Limited-Director-PDMR-Shareholding/78231278 11/03/2019 07:00 UKREG IQ-AI Limited Issue of Convertible Loan Notes "IQ-AI is pleased to announce that the Company has issued GBP268,500 in nominal amount of 6% unsecured convertible loan notes 2024, convertible into 13,425,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at a price of 2 pence per share ("CLNs"). The funds raised as a result of the issue of the CLNs will be used to provide additional working capital for the Company. The funds raised enables the Company to fully execute its current business plan and shareholders should take comfort that the Company is now able to fully execute its current strategic objectives, following this, initially, non-dilutive fundraise. Trevor Brown, Chairman of the Company, has subscribed for GBP250,000 of the CLNs and Michael Schmainda, Chief Executive Officer of the Company's 100% owned subsidiary, Imaging Biometrics LLC, has subscribed for GBP18,500 of the CLNs. ..." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Issue-of-Convertible-Loan-Notes/79437794 (IQAI's March 2019 fundraising conversion price of 2p was at a massive premium (56.86%) to the then IQAI share price (1.275p).) Trevor Brown also invested a further £250,000 into IQAI on 29th. May 2019, again at a massive premium to the pre-existing share price. I.e. the IAQI share price mid price at opening then was 1.1p; the fundraising was at 1.5p: i.e. a 26.7% premium. This sort of management 'cluster investment' into a share is a very bullish indicator, as it is a terrific vote of confidence in the company and its value.
17/6/2019
14:27
hedgehog 100: What happens to IQAI (the business and the share price) after the imminent FDA approval for IQAI's StoneChecker software: which should certainly be announced this month, and could be any day. The fact that FDA approval has taken so long shows how rigorous the process is, how advanced the product is, and also what a great achievement approval will be. And one that will be monumental for IQAI's development, because America is such a vast and well-funded healthcare market, which is at the forefront of applying new technology. This won't therefore be your 'average' good news: it will be gold-plated, company-transformative, 'talk of the town' news. Therefore, I think that we can expect a very big immediate rerating upwards in the share price ... but that should be just for starters. The general upward momentum could continue for weeks, months, and years. And in terms of business, IQAI is chaffing at the bit to start selling StoneChecker into the multi trillion dollar US healthcare market, and has been investing into its business ahead of that, a very positive sign. IQAI also appears to have a range of potential US reseller agreements lined up, which could be ready for signing once FDA marketing approval is received, if not earlier. - 08/02/2019 10:29 UKREG IQ-AI Limited Business Update "...Meanwhile IQ-AI continues to seek business development relationships that will expose its products to a broader audience worldwide. Several marketing and distribution alliances are under active consideration. These will be evaluated, and if appropriate, will be announced in the next few months...." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Business-Update/79217612 30/04/2019 12:00 UKREG IQ-AI Limited Publication of Annual Report "... The Company will focus on four areas of revenue development in 2019: 1. Sales development of existing products During 2018, the Company sold or trialled software at many of the United States' most well-regarded hospitals and specialist clinics. IB Neuro remains the only 'biopsy confirmed' neuro perfusion software available on the market. Publicising this to all potential users is a key element of the Company's 2019 plans. We also intend to explore collaborative business relationships where our sales reach can be expanded by encouraging other companies' sales teams to promote our product for financial reward. This work is already underway with a series of resellers such as aycan Medical Systems, QMENTA, Blackford and Medimsight. ..." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Publication-of-Annual-Report/79794846 All this bodes well for a period of very positive IQAI newsflow in the near future, driving the share price to much higher levels ahead of the next fundraising.
12/6/2019
18:34
hedgehog 100: Soupdragon5512 Jun '19 - 15:51 - 269 of 275 "StoneChecker FDA comment Product was enhanced and resubmitted, FDA have no further questions, so now just in queue waiting for approval to come through. They've used the most experienced regulatory consultant to submit the FDA and say that the CorTech deal shows how positive they are that they'll soon get FDA." You can't over-emphasise the importance of that "no further questions" info. The FDA seem to have come back endlessly with queries, each time stopping the '90 day clock'. It's been a lengthy and frustrating process, which has hit the IQAI share price hard. But now it looks like the process is all but over. The FDA are finally satisfied, and it's now just the final admin. that needs to be done before their approval is given.
07/6/2019
13:49
hedgehog 100: What is far more important is what happens to IQAI (the business and the share price) after the imminent FDA approval for IQAI's StoneChecker software: which should be announced this month, and could be any day. The fact that FDA approval has taken so long shows how rigorous the process is, how advanced the product is, and also what a great achievement approval will be. And one that will be monumental for IQAI's development, because America is such a vast and well-funded healthcare market, which is at the forefront of applying new technology. This won't therefore be your 'average' good news: it will be gold-plated, company-transformative, 'talk of the town' news. Therefore, I think that we can expect a very big immediate rerating upwards in the share price ... but that should be just for starters. The general upward momentum could continue for weeks, months, and years. And in terms of business, IQAI is chaffing at the bit to start selling StoneChecker into the multi trillion dollar US healthcare market, and has been investing into its business ahead of that, a very positive sign. IQAI also appears to have a range of potential US reseller agreements lined up, which could be ready for signing once FDA marketing approval is received. - 08/02/2019 10:29 UKREG IQ-AI Limited Business Update "...Meanwhile IQ-AI continues to seek business development relationships that will expose its products to a broader audience worldwide. Several marketing and distribution alliances are under active consideration. These will be evaluated, and if appropriate, will be announced in the next few months...." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Business-Update/79217612 30/04/2019 12:00 UKREG IQ-AI Limited Publication of Annual Report "... The Company will focus on four areas of revenue development in 2019: 1. Sales development of existing products During 2018, the Company sold or trialled software at many of the United States' most well-regarded hospitals and specialist clinics. IB Neuro remains the only 'biopsy confirmed' neuro perfusion software available on the market. Publicising this to all potential users is a key element of the Company's 2019 plans. We also intend to explore collaborative business relationships where our sales reach can be expanded by encouraging other companies' sales teams to promote our product for financial reward. This work is already underway with a series of resellers such as aycan Medical Systems, QMENTA, Blackford and Medimsight. ..." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Publication-of-Annual-Report/79794846 All this bodes well for a period of very positive IQAI newsflow in the near future, driving the share price to much higher levels ahead of the next fundraising.
06/6/2019
18:52
hedgehog 100: LR2 6 Jun '19 - 17:58 - 244 of 244 " ... You really don't like people who have an alternative viewpoint to yourself do you. ... " LR2, Look who's talking. You had a relatively free run bashing IQAI until I started posting here just over a month ago. Now finally you've encountered someone who's willing and able to stand up to your nonsense, and you don't like it one little bit. And it's not your factual research I object to, it's your bonkers statements on the FDA approval, the fundraisings, and the company's sales, etc. I'm always realistic about timescales, because decades of experience has taught me that slippage is par for the course. Which makes it so laughable that you try to make out that it's 'lying' here that you need to 'warn' us about. Why not issue some warnings about FDBK? But the crux of your 'warnings' to us about TB is that he will cost us money, i.e. a poorly performing share price. Well, let's "seek truth from facts" and examine his record shall we: the share price performance during his two previous listed directorships prior to here. - 1. ADVANCED ONCOTHERAPY (AVO) (formerly CareCapital): 28.6.12 - 30.8.13. Share price rise from approx. 25p to approx. 92p: GAIN OF C. 268%. 28/06/2012 07:01 UK Regulatory (RNS & others) CareCapital Group plc Appointment of Director "CareCapital (AIM: CARE) is pleased to announce the appointment of Trevor Brown as a Non-executive Director with immediate effect. Trevor Brown (66) has been a strategic investor in real estate and equities for more than 30 years. Mr Brown is a director of Free Association Books Limited in London. He has a beneficial interest as at the date of this announcement in 15,334,001 ordinary shares of CareCapital, representing 9.38% of the Company's current issued share capital. There is no further information required to be disclosed in relation to Rule 17 and Schedule 2 (g) of the AIM Rules for Companies. Commenting on the appointment, Dr Mike Sinclair, CareCapital's CEO, said, "I am pleased that Trevor has agreed to join the Board as a Non-executive Director. He is, and has been, a supporter of our plans to refocus CareCapital on the provision of advanced cancer treatment services. His experience and track record will greatly benefit our Board, our management team and our shareholders. I welcome him to CareCapital." ..." https://uk.advfn.com/stock-market/london/advanced-oncotherapy-AVO/share-news/CareCapital-Group-plc-Appointment-of-Director/52918775 30/08/2013 07:15 UK Regulatory (RNS & others) Advanced Oncotherapy PLC Directorate Change " ...Advanced Oncotherapy announces that Non-Executive Director Trevor Brown has resigned from the Board for health reasons. Trevor became a director in June 2012 and has been, and remains, a significant investor in the Company and major supporter of its new cancer services strategy. Advanced Oncotherapy's CEO, Dr Mike Sinclair, said, "Trevor was an early supporter of our change of strategy to become a cancer treatment services business. We benefited both from his advice during a time of transition and his investment in the Company. On behalf of the Board and all of our shareholders, I thank him for his involvement. We wish him a speedy return to good health." Trevor Brown added, "I have enjoyed being a director of Advanced Oncotherapy and participating in the design and formulation of a strategy that I believe will yield substantial returns for shareholders. I remain a committed supporter of, and shareholder in, the Company and look forward to its continuing development and growth." ..." https://uk.advfn.com/stock-market/london/advanced-oncotherapy-AVO/share-news/Advanced-Oncotherapy-PLC-Directorate-Change/59008450 2. FEEDBACK (FDBK): 13.1.14 - 8.6.17 Share price rise from approx. 0.85p to approx. 3.75p: GAIN OF C. 341%. 13/01/2014 08:00 UK Regulatory (RNS & others) Feedback PLC Directorate Change "The Company announces that Trevor Brown and Tom Charlton have joined the board with immediate effect as Non-Executive Directors. Mr Brown, aged 67, has been a strategic investor in real estate and equities for more than 30 years. He was most recently a director of Advanced Oncotherapy plc where he was involved in the strategy of transition to the provision of advanced cancer treatment services. …" https://uk.advfn.com/stock-market/london/feedback-FDBK/share-news/Feedback-PLC-Directorate-Change/60635638 08/06/2017 13:11 UK Regulatory (RNS & others) Feedback PLC Directorate Change "Feedback plc (AIM: FDBK), the medical imaging software company, announces that Trevor Brown, has resigned as a Non-Executive Director of Feedback, with immediate effect ... Dr Alastair Riddell, Non-Executive Chairman, commented: "I should like to thank Trevor for his invaluable support of the Company following its readmission in 2014 which has enabled it to achieve substantial progress to date. ..." https://uk.advfn.com/stock-market/london/feedback-FDBK/share-news/Feedback-PLC-Directorate-Change/74957678 = AVERAGE INCREASE OF c. 304.5%. In summary, on the key metric of share price performance, Trevor Brown has really delivered the goods: an on average QUADRUPLING of these two share prices. And of all the miserably under performing directors of penny shares, you choose to consistently 'warn' us of one of the very few consistent successes! Now, why not tell us how massive your losses on Feedback are, and how you wish you'd traded it like Trevor Brown?
12/5/2019
12:53
hedgehog 100: The 'gang of four' top management at IQAI is a veritable dream team of talent and ability: Trevor Brown, CEO of IQAI HTTP://www.flyingbrands.co.uk/ David Smith, Chief Operating Officer and CEO of the group's two operating businesses, StoneChecker Software and Imaging Biometrics Nick Stevens, CEO of Stone Checker Software Ltd HTTP://www.imagingbiometrics.com/what-we-offer/product-services/ib-stonechecker/ Michael Schmainda, CEO of Imaging Biometrics HTTP://www.imagingbiometrics.com/ And all four have invested significant sums into Flying Brands / IQAI within the last few/several months ... at a price of 2p per share or more: 11/09/2018 07:01 UK Regulatory (RNS & others) Flying Brands Limited Director/PDMR Shareholding "Flying Brands, the parent company of StoneChecker(R) and Imaging Biometrics(R) focused on advanced and state of the art medical software and services, was notified on 10 September 2018 that David Smith, CEO to the Operating Subsidiaries of the Company, acquired 1,000,000 ordinary shares in the Company on 10 September 2018, representing 0.83% of the Company's issued share capital, at a price of 2.48 pence per share." http://uk.advfn.com/stock-market/london/flying-brand-FBDU/share-news/Flying-Brands-Limited-Director-PDMR-Shareholding/78229870 11/09/2018 09:00 UK Regulatory (RNS & others) Flying Brands Limited Director/PDMR Shareholding "Flying Brands, the parent company of StoneChecker(R) and Imaging Biometrics(R) focused on advanced and state of the art medical software and services, was notified on 10 September 2018 that Nick Stevens, CEO to Stone Checker Software Ltd, acquired 1,200,000 ordinary shares in the Company on 10 September 2018, representing 1% of the Company's issued share capital, at a price of 2.5 pence per share. Previously to this notification, Mr Stevens held 2,000,000 ordinary shares in the Company. Therefore Nick Steven's total shareholding represents 2.66% of the Company's issued share capital." http://uk.advfn.com/stock-market/london/flying-brand-FBDU/share-news/Flying-Brands-Limited-Director-PDMR-Shareholding/78231278 11/03/2019 07:00 UKREG IQ-AI Limited Issue of Convertible Loan Notes "IQ-AI is pleased to announce that the Company has issued GBP268,500 in nominal amount of 6% unsecured convertible loan notes 2024, convertible into 13,425,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at a price of 2 pence per share ("CLNs"). The funds raised as a result of the issue of the CLNs will be used to provide additional working capital for the Company. The funds raised enables the Company to fully execute its current business plan and shareholders should take comfort that the Company is now able to fully execute its current strategic objectives, following this, initially, non-dilutive fundraise. Trevor Brown, Chairman of the Company, has subscribed for GBP250,000 of the CLNs and Michael Schmainda, Chief Executive Officer of the Company's 100% owned subsidiary, Imaging Biometrics LLC, has subscribed for GBP18,500 of the CLNs. ..." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Issue-of-Convertible-Loan-Notes/79437794 (IQAI's March 2019 fundraising conversion price of 2p was at a massive premium (56.86%) to the then IQAI share price (1.275p).) This sort of management 'cluster investment' into a share is a very bullish indicator, as it is a terrific vote of confidence in the company and its value.
09/5/2019
19:00
hedgehog 100: 11/03/2019 07:00 UKREG IQ-AI Limited Issue of Convertible Loan Notes "IQ-AI is pleased to announce that the Company has issued GBP268,500 in nominal amount of 6% unsecured convertible loan notes 2024, convertible into 13,425,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at a price of 2 pence per share ("CLNs"). The funds raised as a result of the issue of the CLNs will be used to provide additional working capital for the Company. The funds raised enables the Company to fully execute its current business plan and shareholders should take comfort that the Company is now able to fully execute its current strategic objectives, following this, initially, non-dilutive fundraise. Trevor Brown, Chairman of the Company, has subscribed for GBP250,000 of the CLNs and Michael Schmainda, Chief Executive Officer of the Company's 100% owned subsidiary, Imaging Biometrics LLC, has subscribed for GBP18,500 of the CLNs. ..." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Issue-of-Convertible-Loan-Notes/79437794 IQAI's March 2019 fundraising had two major positives: 1. The fundraising conversion price of 2p was at a massive premium (56.86%) to the then IQAI share price (1.275p). 2. The investment of the two CEO's was akin to massive directors share buying, a huge vote of confidence in the company, especially at such a massive premium. This bodes well for the price of the next fundraising, and I'm expecting a period of very positive IQAI newsflow in the near future, driving the share price to much higher levels ahead of that fundraising. In fact, I would prefer a situation like this to one where a company doesn't need to raise funds for quite a while, and is happy to let the share price drift in the interim. It's interesting that someone has recently mentioned TERN here, because there are some similarities with TERN near its medium term low, though I consider IQAI to be better . I 'tipped' TERN on my RTO thread on 20.12.17 at 2.0p (see post 919), when its market cap. was £2.7M., and within six months it had more than 20-bagged, to over 40p. - THE REVERSE TAKEOVERS & SHELLS THREAD https://uk.advfn.com/cmn/fbb/thread.php3?id=31587598&from=919 TERN took advantage of its share price rise in 2018 to raise funds at far less dilution than otherwise - 08/05/2018 07:01 UK Regulatory (RNS & others) Tern PLC: Equity Fundraise Tern Plc (AIM:TERN), the investment company specialising in the Internet of Things ("IoT"), is pleased to announce that it has raised GBP1,750,000 before expenses through an unconditional placing of 9,459,460 new ordinary shares of 0.02p each at a price of 18.50 pence per ordinary share (the "Placing") with a single institutional investor, utilising the existing share authorities granted at the 2018 AGM. ... https://uk.advfn.com/stock-market/london/tern-TERN/share-news/Tern-PLC-Equity-Fundraise/77363922 25/07/2018 07:01 UK Regulatory (RNS & others) Tern PLC: Equity Fundraise of c. GBP2.9m Tern Plc (AIM:TERN), the investment company specialising in the Internet of Things ("IoT"), is pleased to announce that it has raised approximately GBP2.9 million before expenses through an unconditional placing of 11,192,307 new ordinary shares of 0.02p each at a price of 26 pence per ordinary share (the "Placing"), utilising the existing share authorities granted at the 2018 AGM. ... https://uk.advfn.com/stock-market/london/tern-TERN/share-news/Tern-PLC-Equity-Fundraise-of-c-GBP2-9m/77926992
Iq-ai share price data is direct from the London Stock Exchange
Your Recent History
LSE
IQAI
Iq-ai
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190716 04:19:16